Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ANGN

Angion Biomedica (ANGN) Stock Price, News & Analysis

Angion Biomedica logo

About Angion Biomedica Stock (NASDAQ:ANGN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.00
$10.00
52-Week Range
N/A
Volume
224,800 shs
Average Volume
86,718 shs
Market Capitalization
$30.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ANGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Angion Biomedica and its competitors with MarketBeat's FREE daily newsletter.

ANGN Stock News Headlines

Angion Biomedica Stock Price History
Akari Therapeutics PLC ADR
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
OXBDF Oxford Biomedica plc
8-K: Angion Biomedica Corp.
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CSII, ANGN, OSH, NUVA
See More Headlines

ANGN Stock Analysis - Frequently Asked Questions

Angion Biomedica Corp. (NASDAQ:ANGN) released its quarterly earnings results on Friday, November, 12th. The company reported ($5.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($7.30) by $2.00. The business earned $1.46 million during the quarter, compared to the consensus estimate of $1.08 million.

Angion Biomedica shares reverse split before market open on Friday, June 2nd 2023.The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Angion Biomedica (ANGN) raised $75 million in an initial public offering on Friday, February 5th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Stifel acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Angion Biomedica investors own include Evofem Biosciences (EVFM), Plug Power (PLUG), CNS Pharmaceuticals (CNSP), Viking Therapeutics (VKTX), ContextLogic (WISH), Abeona Therapeutics (ABEO) and Applied Genetic Technologies (AGTC).

Company Calendar

Last Earnings
11/12/2021
Today
7/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ANGN
CIK
1601485
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$38.81 million
Net Margins
N/A
Pretax Margin
-4,456.97%
Return on Equity
-47.53%
Return on Assets
-40.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
20.00
Quick Ratio
20.00

Sales & Book Value

Annual Sales
$2.30 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.32 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
30,110,000
Free Float
24,182,000
Market Cap
$30.11 million
Optionable
Not Optionable
Beta
0.60
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ANGN) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners